The San Diego based firm is backed by Nvidia and will use the IPO proceeds to advance three early-stage cancer drug candidates. Iambic Therapeutics operates as a clinical-stage technology company that employs artificial intelligence to accelerate oncology drug discovery.
Tuesday, October 20, 2026
Story
Iambic Therapeutics Shares Jump 18% on Debut After $150M IPO
US Markets5 days ago
The AI-driven cancer drugmaker reached a total valuation of nearly $900 million as shares climbed during its first day of trading. Iambic Therapeutics raised $150 million in a US initial public offering, with the stock finishing the session nearly 18% higher than its offering price.
Looking for more context or analysis?
Tilt chat provides reliable, tailored insights, alerts, and automations.